Table of Contents Table of Contents
Previous Page  31 / 86 Next Page
Show Menu
Previous Page 31 / 86 Next Page
Page Background


NCCN Guidelines for Patients


Peripheral T-cell Lymphoma, Version 1.2016


Overview of cancer treatments Targeted therapy

Targeted therapy

Targeted therapy is a class of drugs that stops the

action of molecules that helps cancer cells grow. It is

less likely to harm normal cells than chemotherapy.

There are 3 targeted therapies that are used to treat

peripheral T-cell lymphoma. These treatments are

briefly described next. Some side effects are listed.

Ask your treatment team for a full list of common and

rare side effects. In Part 4, information on who should

receive these drugs is provided.


Monoclonal antibodies are man-made antibodies that

attach to proteins on cancer cells. The monoclonal

antibody used to treat peripheral T-cell lymphoma

attach to antigens. When antibodies are attached to

antigens on a cell, the cell is marked to be destroyed

by your immune system.

Alemtuzumab is a monoclonal antibody that attaches

to a molecule called CD52. CD52 is found on

peripheral T-cell lymphoma cells, healthy B-cells and

T-cells, as well as other cells. Alemtuzumab is rarely

used to treat peripheral T-cell lymphoma.

Alemtuzumab is a liquid that will be slowly injected

into your vein. It may take up to two hours to get

the full dose. Alemtuzuamb can also be given as an

injection under the skin. Alemtuzumab is often given

three times a week for 12 weeks.

Common side effects include an allergic reaction

when receiving the medicine. Also, you may feel

nausea, vomit, get diarrhea, and have trouble

sleeping. Blood counts are often low when taking

this medicine. Taking alemtuzumab will increase

your chances of getting a cytomegalovirus or other



DNA is tightly wrapped around proteins called

histones to form chromosomes. HDAC (






etylase) removes a chemical group from

histones so that DNA can wrap more tightly. HDAC

inhibitors enter cells and block the action of HDAC.

Blocking can turn on genes that were shut down

by cancer and lead to cell death. Belinostat is an

HDAC inhibitor. It is used to treat some subtypes of

peripheral T-cell lymphoma cells.

Belinostat is a liquid that will be slowly injected into

your vein for about 30 minutes. It is given during the

first 5 days of a 21-day cycle. Your doctor will discuss

with you how many cycles are needed.

Common side effects include nausea, vomiting,

fatigue, fever, low numbers of red blood cells. It may

also cause liver damage and increase your chance

of getting an infection. Belinostat can harm unborn


Brentuximab vedotin

Brentuximab vedotin contains a monoclonal antibody

that delivers cell-specific chemotherapy. On the

surface of some peripheral T-cell lymphomas are

proteins called CD30. Brentuximab attaches to CD30

and enters cancer cells. Once inside, it releases the

chemotherapy. By targeting only cells with CD30

proteins, fewer normal cells are harmed.

Brentuximab vedotin is slowly injected into a vein for

about 30 minutes. It is often given every 3 weeks. The

most common side effects include fatigue, low blood

counts, tingling in hands and feet, nausea, diarrhea,

fever, rash, and lung infections. Rare but severe side

effects include brain infection, serious disorder of skin

and mucous membranes, and kidney problems.